Anti-galectin-3 therapy

A new chance for multiple myeloma and ovarian cancer?

Leonardo Mirandola, Diane D. Nguyen, Rakhshanda L. Rahman, Fabio Grizzi, Yu Yuefei, José A. Figueroa, Marjorie R. Jenkins, Everardo Cobos, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.

Original languageEnglish (US)
Pages (from-to)417-427
Number of pages11
JournalInternational Reviews of Immunology
Volume33
Issue number5
DOIs
StatePublished - Sep 3 2014

Fingerprint

Galectin 3
Multiple Myeloma
Ovarian Neoplasms
Galectins
Neoplasms
Therapeutics
Hematologic Neoplasms
Adhesives
Extracellular Matrix

Keywords

  • Adhesion
  • Drug resistance
  • Galectins
  • Multiple myeloma
  • NF-κB
  • Ovarian cancer

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Mirandola, L., Nguyen, D. D., Rahman, R. L., Grizzi, F., Yuefei, Y., Figueroa, J. A., ... Chiriva-Internati, M. (2014). Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer? International Reviews of Immunology, 33(5), 417-427. https://doi.org/10.3109/08830185.2014.911855

Anti-galectin-3 therapy : A new chance for multiple myeloma and ovarian cancer? / Mirandola, Leonardo; Nguyen, Diane D.; Rahman, Rakhshanda L.; Grizzi, Fabio; Yuefei, Yu; Figueroa, José A.; Jenkins, Marjorie R.; Cobos, Everardo; Chiriva-Internati, Maurizio.

In: International Reviews of Immunology, Vol. 33, No. 5, 03.09.2014, p. 417-427.

Research output: Contribution to journalArticle

Mirandola, L, Nguyen, DD, Rahman, RL, Grizzi, F, Yuefei, Y, Figueroa, JA, Jenkins, MR, Cobos, E & Chiriva-Internati, M 2014, 'Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer?', International Reviews of Immunology, vol. 33, no. 5, pp. 417-427. https://doi.org/10.3109/08830185.2014.911855
Mirandola, Leonardo ; Nguyen, Diane D. ; Rahman, Rakhshanda L. ; Grizzi, Fabio ; Yuefei, Yu ; Figueroa, José A. ; Jenkins, Marjorie R. ; Cobos, Everardo ; Chiriva-Internati, Maurizio. / Anti-galectin-3 therapy : A new chance for multiple myeloma and ovarian cancer?. In: International Reviews of Immunology. 2014 ; Vol. 33, No. 5. pp. 417-427.
@article{39e4ca495b124a3192d7e8e6f12f887f,
title = "Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer?",
abstract = "Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.",
keywords = "Adhesion, Drug resistance, Galectins, Multiple myeloma, NF-κB, Ovarian cancer",
author = "Leonardo Mirandola and Nguyen, {Diane D.} and Rahman, {Rakhshanda L.} and Fabio Grizzi and Yu Yuefei and Figueroa, {Jos{\'e} A.} and Jenkins, {Marjorie R.} and Everardo Cobos and Maurizio Chiriva-Internati",
year = "2014",
month = "9",
day = "3",
doi = "10.3109/08830185.2014.911855",
language = "English (US)",
volume = "33",
pages = "417--427",
journal = "International Reviews of Immunology",
issn = "0883-0185",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Anti-galectin-3 therapy

T2 - A new chance for multiple myeloma and ovarian cancer?

AU - Mirandola, Leonardo

AU - Nguyen, Diane D.

AU - Rahman, Rakhshanda L.

AU - Grizzi, Fabio

AU - Yuefei, Yu

AU - Figueroa, José A.

AU - Jenkins, Marjorie R.

AU - Cobos, Everardo

AU - Chiriva-Internati, Maurizio

PY - 2014/9/3

Y1 - 2014/9/3

N2 - Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.

AB - Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.

KW - Adhesion

KW - Drug resistance

KW - Galectins

KW - Multiple myeloma

KW - NF-κB

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84907846162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907846162&partnerID=8YFLogxK

U2 - 10.3109/08830185.2014.911855

DO - 10.3109/08830185.2014.911855

M3 - Article

VL - 33

SP - 417

EP - 427

JO - International Reviews of Immunology

JF - International Reviews of Immunology

SN - 0883-0185

IS - 5

ER -